Business
Moderna Stock Soars on Positive Melanoma Vaccine Results
Moderna shares jumped over 145% after a final-stage trial showed its mRNA therapy, paired with MSD's Keytruda, cut melanoma recurrence and spread.
Moderna shares jumped over 145% after a final-stage trial showed its mRNA therapy, paired with MSD's Keytruda, cut melanoma recurrence and spread.